Black Diamond Therapeutics Statistics
Share Statistics
Black Diamond Therapeutics has 56.86M
shares outstanding. The number of shares has increased by 0.73%
in one year.
| Shares Outstanding | 56.86M |
| Shares Change (YoY) | 0.73% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | 84.78% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 9,643 |
| FTD / Avg. Volume | 0.28% |
Short Selling Information
The latest short interest is 8.08M, so 14.2% of the outstanding
shares have been sold short.
| Short Interest | 8.08M |
| Short % of Shares Out | 14.2% |
| Short % of Float | 20.41% |
| Short Ratio (days to cover) | 5.64 |
Valuation Ratios
The PE ratio is -1.69 and the forward
PE ratio is -2.17.
Black Diamond Therapeutics's PEG ratio is
0.05.
| PE Ratio | -1.69 |
| Forward PE | -2.17 |
| PS Ratio | 0 |
| Forward PS | 1.2 |
| PB Ratio | 1.41 |
| P/FCF Ratio | -1.89 |
| PEG Ratio | 0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Black Diamond Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.92,
with a Debt / Equity ratio of 0.27.
| Current Ratio | 4.92 |
| Quick Ratio | 4.92 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | -0.32 |
| Debt / FCF | -0.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,903,166.67 |
| Employee Count | 24 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -50.32% in the
last 52 weeks. The beta is 2.64, so Black Diamond Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.64 |
| 52-Week Price Change | -50.32% |
| 50-Day Moving Average | 1.7 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 69.09 |
| Average Volume (20 Days) | 3,389,774 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -78.78M |
| Net Income | -69.68M |
| EBITDA | -69.33M |
| EBIT | -69.68M |
| Earnings Per Share (EPS) | -1.27 |
Full Income StatementBalance Sheet
The company has 36.44M in cash and 22.19M in
debt, giving a net cash position of 14.25M.
| Cash & Cash Equivalents | 36.44M |
| Total Debt | 22.19M |
| Net Cash | 14.25M |
| Retained Earnings | -487.11M |
| Total Assets | 176.25M |
| Working Capital | 138.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -62.3M
and capital expenditures 0, giving a free cash flow of -62.3M.
| Operating Cash Flow | -62.3M |
| Capital Expenditures | n/a |
| Free Cash Flow | -62.3M |
| FCF Per Share | -1.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
